US 10682388
Targeting of PELP1 in cancer therapy
granted A61KA61K38/04A61K38/10
Quick answer
US patent 10682388 (Targeting of PELP1 in cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K38/04, A61K38/10, A61K38/16, A61K45/06